Evidence map›Paper›PMID 20938714›Full record

ArticleInvestigational new drugs2012

A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis.

Shama Moktan, Claudia Ryppa, Felix Kratz, Drazen Raucher

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Article
  16. Article
  17. Review
  18. Article
  19. A kidney-selective biopolymer for targeted drug delivery.American journal of physiology. Renal physiology · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shama MoktanUniversity of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.
Claudia Ryppa
Felix Kratz
Drazen Raucher

Funding

Thermally Targeted Delivery of Therapeutic PeptidesR43CA135799 · NCI · THERMALLY TARGETED THERAPEUTICS · PI RAUCHER, DRAZEN · 2009 to 2009
$139k
NCI NIH HHS R43 CA135799-01A2
6 · The paper itself

Abstract

Poor aqueous solubility limits the therapeutic index of paclitaxel as an anti-cancer drug. Synthesis of soluble prodrugs of paclitaxel, or conjugation of the drug to macromolecular carriers have been reported to increase its water-solubility. Macromolecular drug carriers have an added advantage of targeting the drug to the tumor site due to the abnormal tumor blood and lymphatic vasculature. This study describes a thermally responsive macromolecular carrier, elastin-like polypeptide (ELP) for the delivery of paclitaxel. Paclitaxel was bound to ELP by conjugation with the 6-maleimidocaproyl hydrazone derivative of paclitaxel, an acid-sensitive paclitaxel prodrug, for the potential treatment of breast cancer. Focused hyperthermia above a specific transition temperature at the site of a tumor causes ELP to aggregate and accumulate, thereby increasing the local concentration of the drug cargo. The paclitaxel prodrug described here bears an acid-sensitive linker that is cleavable at the lysosomal/endosomal pH, which allows a controlled intracellular release of the drug. The ELP-delivered paclitaxel in the presence of hyperthermia inhibits MCF-7 cell proliferation by stabilizing the microtubule structures, arresting the cells at the G2/M stage, and inducing apoptosis in a manner similar to conventional paclitaxel. It also inhibits proliferation of a paclitaxel resistant MCF-7 cell line. These data provide an in vitro proof of concept for the use of ELP as a delivery vehicle of paclitaxel.

Indexed as

Drug CarriersAntineoplastic Agents, PhytogenicApoptosisBreast NeoplasmsCell Line, TumorCell ProliferationCell SurvivalChemistry, PharmaceuticalDelayed-Action PreparationsDose-Response Relationship, DrugDrug CompoundingDrug Resistance, NeoplasmElastinFemaleG2 Phase Cell Cycle CheckpointsHumansAntineoplastic Agents, PhytogenicDelayed-Action PreparationsDrug CarriersElastinPaclitaxelProdrugsRecombinant ProteinsTubulin Modulators

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.